Immunotherapy

Sosei and Cancer Research UK announce first patient dosed with oral immunotherapy drug

15-Aug-2023 By Liza Laws

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

US startup bags $32 million to blend cancer surgery and immunotherapy

20-Jul-2023 By Jonathan Smith

The U.S. startup Surge Therapeutics has raised $32 million in a Series B round to bankroll the development of a hydrogel-based immunotherapy delivered during cancer surgery.

US startup bags $32 million to blend cancer surgery and immunotherapy

20-Jul-2023 By Jonathan Smith

The U.S. startup Surge Therapeutics has raised $32 million in a Series B round to bankroll the development of a hydrogel-based immunotherapy delivered during cancer surgery.

LG Chem targets becoming top 20 oncology company

14-Mar-2023 By Ben Hargreaves

After completing the acquisition of Aveo, the Korean chemical company wants its subsidiary to become a global leader in the therapeutic area within five years.

BioNTech links up with Ryvu on small molecule immunotherapy

06-Dec-2022 By Ben Hargreaves

BioNTech and Ryvu Therapeutics will collaborate to develop oncology programs, with the pair announcing that they will work together as part of a multi-target research collaboration.

Medicenna takes on deadly brain cancer in clinical trial

08-Jul-2021 By Jenni Spinner

The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.

Samsung Biologics to produce clinical supply as UCB advances Ph I immunotherapy study

05-Aug-2019 By Maggie Lynch

Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.

Caprion and HistoGeneX form joint company offering new services, greater global reach

05-Aug-2019 By Maggie Lynch

Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.

Erytech-SQZ collaboration to ‘realize immune-modulating potential’

11-Jul-2019 By Maggie Lynch

Erytech entered an agreement with SQZ to advance RBC-based therapeutics for immune modulation using the latter’s platform.

Cytonus’ tech helps oncolytic viruses evade immune system

29-May-2019 By Ben Hargreaves

Cytonus will present at BIO regarding the development of Cargocytes, which offer a delivery system for immunotherapy treatments.

Pfizer licenses immune tolerance therapy for type 1 diabetes

07-Mar-2019 By Maggie Lynch

Pfizer exercises option from a previous agreement with AnTolRx to license immune tolerance therapy for type 1 diabetes.

Merck in $300m Immune Design boost for Keytruda

21-Feb-2019 By Ben Hargreaves

Announced today, the deal sees Merck pay $5.85 per share to acquire Immune Design and its portfolio of late-stage immunotherapies.

Exclusive interview

QPS triples translational medicine capacity to support gene therapy demand

05-Feb-2019 By Melissa Fassbender

QPS is expanding ‘aggressively’ at its US-based headquarters, rebuilding on a rolling basis to support a growing demand for gene therapy treatments, says VP.

Regeneron and Sanofi receives first US FDA approval for PD-1 treatment

03-Oct-2018 By Maggie Lynch

The US FDA approved the first drug created by the 2015 partnership between Regeneron and Sanofi to research and develop immuno-oncology therapies.

Oncology vaccine ensured 100% survival rate in lab studies

18-Sep-2018 By Maggie Lynch

Scientists demonstrated that an adjuvant to an immunotherapy vaccine resulted in a 100% survival rate in mice with aggressive melanoma.